This article summarizes the existing, upcoming, and failed immunologic-based medications for atopic dermatitis.doi:10.1007/s40267-024-01075-8Hemali Shahhttps://ror.org/012jban78grid.259828.c0000 0001 2189 3475Medical University of South Carolina Charleston SC USAFrancelia J. Eckembrecher...
atopic dermatitiseczemaBiologic medications are recent advances that have clinical significance in the treatment of moderate-to-severe AD. A systemic literature review was performed to examine the efficacy and safety of biologic therapies currently in phase II and phase III of clinical trials for ...
Dupilumab and tralokinumab are currently the only FDA-approved biologic therapies for the treatment of moderate-to-severe atopic dermatitis. Tralokinumab is approved for patients greater than 18 years old, and dupilumab is approved for patients as young as 6 months old. Both medications are ...
Biologic medicines have revolutionized the management of dermatological conditions such as psoriasis and atopic dermatitis and their use is likely to not only continue but grow given their success. Most of these medications are delivered through self-injector systems, commonly a prefilled pen made of ...
By highlighting novel uses of these agents, particularly for the treatment of dermatologic conditions for which optimal therapies are yet to be established, we hope to raise awareness of the potential use of this class of medications to treat inflammatory skin diseases in children....
Incidence of COVID-19 in a cohort of dermatology patients receiving immunomodulating biologic medications Dear Editor, Decisions whether to initiate, continue, or discontinue biologic and other systemic immunomodulating medications should be made as a result of patient-centered, evidence-based discussion ...
The study involved a review of medications used over the last 10 years and did not include data creation or statistical analysis. Acknowledgments The authors would like to express their gratitude to the Department of Pediatrics at the Hospital Universitario de Navarra for supporting the establishment ...
Iatrogenic factors that can trigger PRP include medications [23,24,25,26,27] and vaccines [28,29,30,31,32,33,34]. Several cases of PRP are reported in association with malignancies, even as an initial manifestation [35,36,37,38,39]. Griffiths proposed the classification of PRP into five...
biologic agent;paradoxical reaction;psoriasis;atopic dermatitis;cytokine 1. Introduction With recent advances in our molecular understanding of the immune axes activated in various immune-mediated inflammatory diseases, targeting pathogenic cytokines with greater specificity has become possible. Biologic agents,...